What are the clinical manifestations and recommended management for antitubercular therapy‑induced peripheral neuropathy?

Antitubercular Therapy-Induced Peripheral Neuropathy: Clinical Manifestations and Management

For mild peripheral neuropathy during TB treatment, increase pyridoxine to 100 mg/day and reduce the dose of the offending drug; for severe or persistent neuropathy despite these measures, discontinue the causative agent immediately 1, 2.

Clinical Manifestations

Primary Symptoms

Peripheral neuropathy from antitubercular drugs presents with:

• Distal sensory symptoms: Burning feet, numbness, and painful paresthesias in a stocking-glove distribution
• Lower extremity predominance: Symptoms typically begin in the feet and progress proximally
• Timing: Most commonly develops 2-6 months after treatment initiation, though can occur as early as several weeks 3, 4, 5
• Severity grading: Ranges from mild paresthesias to severe pain with functional impairment and ataxic gait 3

Causative Agents by Priority

First-line drugs:

• Isoniazid: Most common cause, dose-related, occurs in <0.2% at conventional doses but increases significantly in high-risk patients 6
• Ethambutol: Can cause peripheral neuropathy in addition to optic neuritis 7

Second-line drugs:

• Linezolid: High-risk agent causing peripheral neuropathy in significant proportion of patients, typically after 10-20 weeks of treatment; often accompanied by optic neuritis and myelosuppression 8, 3
• Fluoroquinolones (moxifloxacin, levofloxacin): Rare but documented cause with delayed, cumulative toxicity possible after 17+ weeks 9
• Cycloserine/terizidone: Associated with neuropsychiatric effects and peripheral neuropathy 1

High-Risk Populations Requiring Prophylaxis

Pyridoxine 25-50 mg/day should be given prophylactically to all patients receiving isoniazid who have 6, 10, 2:

• HIV infection
• Diabetes mellitus
• Chronic renal failure or end-stage renal disease
• Alcoholism or heavy alcohol consumption
• Malnutrition or nutritional deficiency
• Pregnancy and breastfeeding
• Advanced age
• Pre-existing peripheral neuropathy

Management Algorithm

Step 1: Initial Assessment

When peripheral neuropathy is suspected:

• Clinical diagnosis is sufficient—electromyography confirms axonal sensorimotor neuropathy but is not required for management decisions 5
• Rule out alternative causes: Check hemoglobin A1c (diabetes), vitamin B12/folate levels, HIV status if unknown, renal function 9, 4
• Verify correct drug dosing—overdosing increases neurotoxicity risk 1

Step 2: Severity-Based Intervention

Mild neuropathy (sensory symptoms without functional impairment):

1. Increase pyridoxine to 100 mg/day (up from prophylactic 25-50 mg/day) 2, 8
2. Reduce dose of offending drug:
   • Isoniazid: Reduce to 3 mg/kg/day in slow acetylators or 2.5 mg/kg/day if symptoms persist 11
   • Linezolid: Consider dose reduction to 300-600 mg/day or switch to intermittent dosing 8, 12
3. Monitor closely for progression over 2-4 weeks

Severe or persistent neuropathy (despite dose reduction, or with functional impairment, ataxia, or severe pain):

1. Immediately discontinue the causative drug 1
2. Continue pyridoxine 100-250 mg/day 11
3. Substitute with non-neurotoxic alternatives:
   • Replace isoniazid with ethambutol, fluoroquinolone, or injectable agent
   • Replace linezolid with bedaquiline, delamanid, or other second-line agents
   • Ensure regimen maintains at least 4 effective drugs for drug-susceptible TB or appropriate number for drug-resistant TB

Step 3: Symptomatic Pain Management

First-line for neuropathic pain:

• Pregabalin 150-600 mg/day for at least 3 months 13
• Alternative: Gabapentin 300-2,400 mg/day at highest tolerated dose 13

Second-line options:

• Duloxetine 30-60 mg/day if pregabalin/gabapentin ineffective 13
• Tramadol for chronic pain management 13
• Tricyclic antidepressants (amitriptyline) as alternative 4

Adjunctive measures:

• Physical therapy
• Topical agents (capsaicin cream, menthol) for localized symptoms 13
• Supportive care: loose-fitting shoes, padded slippers, avoid tight bedding 13

Step 4: Special Considerations for Linezolid

Linezolid requires heightened vigilance due to cumulative neurotoxicity 8, 3:

• Monitor for peripheral neuropathy AND optic neuritis monthly
• If optic neuritis develops, discontinue immediately; may rechallenge at reduced dose (300 mg/day) after vision normalizes 8
• Consider therapeutic drug monitoring if available—trough levels >2.0 mg/L associated with increased toxicity 8
• Recent evidence suggests immediate dose modification for non-severe neuropathy does not compromise treatment success 12

Prognosis and Recovery

• Median time to improvement: 3-7 months after drug discontinuation or dose reduction 8, 5
• Complete resolution: Possible in many cases, but permanent residual symptoms occur in a notable proportion, particularly with linezolid 3, 5
• Grade 3-4 neuropathy: Longer recovery time than grade 1-2 13
• Early identification is critical—delayed recognition increases risk of irreversible damage 3, 9

Critical Pitfalls to Avoid

1. Do not continue full-dose neurotoxic drugs once symptoms develop—this increases risk of permanent disability 6, 3
2. Avoid high-dose vitamin B6 (>250 mg/day) without clear indication—paradoxically can cause sensory neuropathy, especially with renal insufficiency 13
3. Do not use high-dose vitamin C with bortezomib (not applicable to TB but important drug interaction principle) 13
4. Do not assume all neuropathy is drug-related—rule out TB itself, HIV-related neuropathy, and metabolic causes 4, 14
5. Monitor throughout entire treatment course—delayed cumulative toxicity can occur even after months of therapy 9